Continuous infusion of betalactam antibiotics: Interests, drawbacks, practical aspects;Perfusion continue des bêtalactamines : intérêts, inconvénients, modalités pratiques

Reanimation

Volumn 18, Issue 4, 2009, Pages 343-352

  Jehl, F ^a   Leveque D ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Betalactams; Continuous infusion; Pharmacodynamics; PK PD; Stability

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFOTAXIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; ERTAPENEM; FLUCLOXACILLIN; IMIPENEM; MEROPENEM; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; UREIDOPENICILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERICIDAL ACTIVITY; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG STABILITY; ENTEROBACTERIACEAE INFECTION; GRAM NEGATIVE INFECTION; HALF LIFE TIME; HUMAN; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; PSEUDOMONAS INFECTION; RISK REDUCTION; SERUM BACTERICIDAL ACTIVITY; SHORT SURVEY; THERMOSTABILITY; WILD TYPE;

EID: 66049133682     PISSN: 16240693     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reaurg.2009.03.009     Document Type: Short Survey

References (44)

1. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 (1998) 1-12
2. Craig W.A., and Ebert S.C. Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 36 (1992) 2577-2583
3. Ronchera-Oms C.L., Gregorio S., and Sanlleh N. Should continuous infusion of beta-lactams antibiotics be the first-line approach?. J Clin Pharm Ther 22 (1997) 159-161
4. Vondracek T.G. Beta-lactam antibiotics: is continuous infusion the preferred method of administration?. Ann Pharmacother 29 (1995) 415-424
5. Benko A.S., Cappelletty D.M., Kruse J.A., and Rybak M.J. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram-negative infections. Antimicrob Agents Chemother 40 (1996) 691-695
6. MacGowan A.P., and Bowker K.E. Continuous infusions of beta-lactam antibiotics. Clin Pharmacokinet 35 (1998) 391-396
7. Roberts J.A., Paratzab J., Paratza E., Kruegerc W.A., and Lipmanab J. Continuous infusion of β-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 30 (2007) 11-18
8. Mouton J.W., Vinks A.A., and Punt N.C. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 41 (1997) 733-738
9. Olofsson S.K., Geli P., Andersson D.I., and Cars O. Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli. Antimicrob Agents Chemother 49 (2005) 5081-5091
10. Alou L., Aguilar L., Sevillano D., Giménez M.J., Echeverría O., Gómez-Lus M.L., et al. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against P. aeruginosa? An in vitro pharmacodynamic model. J Antimicrob Chemother 55 (2005) 209-213
11. Ryback M.J. Pharmacodynamics: relation to antimicrobial resistance. Am J infect control 34 (2006) S38-S45
12. Holenstein U., Brunner M., Mayer B.X., Delacher S., Erovc B., Eichler H.G., et al. Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers. Clin Pharmacol Ther 67 (2000) 229-236
13. Vinks A.A., Brimicombe R.W., Heijerman H.G., and Bakker W. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother 40 (1997) 125-133
14. Carlet J. Intérêt clinique de l'administration intra-veineuse continue de la ceftazidime. Antibiotiques 4 (2002) 5-8
15. Walton A.L., Howden B.P., Grayson L.M., and Korman T.M. Continuous-infusion penicillin home-based therapy for serious infections due to penicillin-susceptible pathogens. Int J Antimicrob Agents 29 (2007) 544-548
16. Bryan C.S. Nosocomial pneumonia. Chest 116 (1997) 859-860
17. Leder K., Turnidge J.D., Korman T.M., and Grayson M.L. The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis. J Antimicrob Chemother 43 (1999) 113-118
18. Howden B.P., and Richards M.J. The efficacy of continuous infusion flucloxacillin in home therapy for serious staphylococcal infections and cellulitis. J Antimicrob Chemother 48 (2001) 311-314
19. Grant E.M., Kuti J.L., Nicolau D.P., Nightingale C., and Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam. program in a large community teaching hospital. Pharmacotherapy 22 (2002) 471-483
20. Mariat C., Venet C., Jehl F., Mwewa S., Lazarevic V., Dicone E., et al. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommandations. Crit Care (2006) 10
21. Boselli E., Breilh D., Rimmele T., Poupelin J.C., Saux M.C., Chassard D., et al. Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia Intensive care. Medecine (Baltimore) 30 (2004) 989-991
22. Boselli E., Breilh D., Duflo F.M.D., Saux M.C., Debon R., Chassard D., et al. Steady state plasma and intrapul monary concentration of cefepime administerd in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med 31 (2003) 2102-2106
23. Singlas E. Pharmacocinétique et pharmacodynamie de la ceftazidime en perfusion continue. Antibiotiques 4 (2002) 14-22
24. Eagye K.J., Nicolau D.P., Lockhart S.R., Quinn J.P., Doern G.V., Gallagher G., et al. A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the united states between 1993 and 2004. Ann Clin Microbiol Antimicrob 6 (2007) 11-17
25. Dalle J.H., Magloire G., Husson M.O., Lambilliotte A., Mazingue F., and Nelken B. Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with cancer. J Pediatr Hematol 24 (2002) 9-13
26. Jaruratanasirikul S., and Sriwiriyajan S. Stability of meropenem in normal saline solution after storage at room temperature. Southeast Asian J Trop Med Public Health 34 (2003) 627-629
27. Manduru M., Mihm L.B., White R.L., Friedrich L.V., Flume P.A., and Bosso J.A. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 41 (1997) 2053-2056
28. Gómez C.M.H., Cordingly J.J., and Palazzo M.G.A. Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 43 (1999) 1798-1802
29. Kasiakou S.K., Sermaides G.J., Michalopoulos A., Soteriades E.S., Falagas E., and Matthew D.R. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 5 (2005) 581-589
30. Kuti J.L., Nightingale C.H., Knauft R.F., and Nicolau D.P. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther 26 (2004) 493-501
31. Frei C.R., and Burgess D.S. Continuous infusion beta-lactams for intensive care unit pulmonary infections. Clin Microbiol Infect 11 (2005) 418-421
32. Lortholary O., Le fort A., Tod M., Chomat A.M., Darras-Joly C., and Cordonnier C. Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia. Lancet Infect Dis 8 (2008) 612-620
33. Mc Nabb J.J., Nightingale C.H., Quintiliani R., and Nicolau D.P. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy 21 (2001) 549-555
34. Vella-Brinca J., Begg E., Zhang M., and Chambers S. Cooling enhances benzylpenicillin sability during continuous home intravenous administration. Hosp Pharm 13 (2006) 56-57
35. Vella-Brincat J.W.A., Begg E.J., GAllagher K., Kirkpatrick C.M.J., Zhang M., Frampton C., et al. Stability of benzylpenicillin during continuous home intravenous therapy. J Antimicrob Chemother 53 (2004) 675-677
36. James M.J., and Riley C.M. Stability of intravenous admixtures of aztreonam and ampicillin. Am J Hosp Pharm 45 (1985) 1095-1100
37. Viaene E., Chanteux H., Servais H., Mingeot-Leclercq M.P., and Tulkens P.M. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor operated syringes (intensive care units). Antimicrob Agents Chemother 46 (2002) 2327-2332
38. DeCalbiac P., Lamoureux F., Pourrai X., Bretault L., Marchand S., Grassin J., et al. Traitement des surinfections bronchiques : stabilité des antibiotiques dans les diffuseurs portatifs. Therapie 61 (2006) 139-144
39. Arlicot N., Rochefort G.Y., Schlecht D., Lamoureux F., Marchand S., and Antier D. Stability of antibiotics in portable pumps used for bronchial superinfections: guidelines for prescribers. Pediatrics 120 (2007) 1255-1259
40. Sprauten P.F., Beringer P.M., Louie S.G., Synold T.W., and Gill M.A. Stability and antibacterial activity of cefepime during continuous infusion. Antimicrob Agents Chemother 47 (2003) 1991-1994
41. Manduru M., Fariello A., White R.L., Fox J.L., and Bosso J.A. Stability of ceftazidime sodium and teicoplanin sodium in a peritoneal dialysis solution. Am J Health Syst Pharm 53 (1996) 2731-2734
42. Servais H., and Tulkens P.M. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 45 (2001) 2643-2647
43. Elwell R.J., Volino L.R., and Frye R.F. Stability of cefepime in icodextrin peritoneal dialysis solution. Ann Pharmacother 38 (2004) 2041-2044
44. Daenen D., Erjavec Z., Uges D.R.A., DeVries-Hospers H.G., DeJonge P., and Halie M.R. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. Eur J Clin Microbiol Infect Dis 14 (1995) 188-192